Co-targeting of delta-like ligand 4 (DLL4) and vascular endothelial growth factor a (VEGF) with programmed death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses

Podobne zapisy

• Anti-DLL4, a cancer therapeutic with multiple mechanisms of action
  od: Gurney, Austin, i wsp.
  Wydane: (2011)
• RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations
  od: Fischer, Marcus M., i wsp.
  Wydane: (2017)
• Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth
  od: Segarra, Marta, i wsp.
  Wydane: (2008)
• Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth
  od: Huang, Jie, i wsp.
  Wydane: (2016)
• Delta-like ligand 4 (Dll4) predicts the prognosis of clear cell renal cell carcinoma, and anti-Dll4 suppresses tumor growth in vivo
  od: Hu, Guang-Hui, i wsp.
  Wydane: (2014)